Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.
about
The Potential for Misuse and Abuse of Medications in ADHD: A ReviewAmphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adultsThe use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorderTreatment of adults with attention-deficit/hyperactivity disorderTreatment of adults with attention-deficit/hyperactivity disorderAlpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animalsAdrenergic pharmacology and cognition: focus on the prefrontal cortexTargeting the noradrenergic system for gender-sensitive medication development for tobacco dependenceEfficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adultsDo adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementThe role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsTreatment of attention deficit hyperactivity disorder in adults.A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessationMolecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders.Catecholamine influences on dorsolateral prefrontal cortical networks.Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates.Efficacy of stimulants in adult ADHD.Adult ADHD and substance abuse: diagnostic and treatment issues.Cognitive effects of genetic variation in monoamine neurotransmitter systems: a population-based study of COMT, MAOA, and 5HTTLPR.Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness.Treatment strategies for co-occurring ADHD and substance use disordersTreatment of adult ADHD: is current knowledge useful to clinicians?Once-daily treatment of ADHD with guanfacine: patient implications.Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.Emerging drugs for attention-deficit/hyperactivity disorder.Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings.ADHD in adults: a review of the literature.Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function.Once-daily medications for the pharmacological management of ADHD in adultsThe role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter?Distinguishing comorbidity and successful management of adult ADHD.Developments and challenges in the diagnosis and treatment of ADHD.The role of prefrontal catecholamines in attention and working memory.
P2860
Q22241206-FD48BD4A-9A85-4598-8898-CF3E8B3B52D9Q24236404-0C3528AA-2413-4446-A6FE-148AE1890437Q24629736-B5AA955B-D948-4A59-8836-ACA968984E8CQ24642937-4D588899-0088-45D0-AD0E-236D75F0C9A4Q24644586-BD804343-42CB-46DE-A260-904FD33D93E1Q24682060-CE45E0B4-37AB-4CAB-91EB-9253EFD80A88Q24684217-662A1F7F-C488-4D74-93EB-1D2660E99070Q26999258-88C3CC6C-2ADA-4E2E-9196-25A680B46BACQ28246506-16633788-1022-4BB2-A812-6A4B3B523171Q28274915-6D5734FB-EB33-4DCA-918B-2B88AC828542Q28295525-42A421A9-83B4-4138-9790-F0A2FE267DC0Q33598487-E06C4405-A667-4EF7-864E-4B13846DCFC0Q34220004-A9747497-0B46-4594-A723-C5FA58934E26Q34413877-D83F76CD-9A11-42B3-8B61-B7DDAC2A6321Q34454236-52E494F7-CA81-419F-9F31-099F33636D05Q35028276-6ED626B6-9F99-45C2-BAED-1E322FEF34F9Q35132548-EB99585A-8F8F-48DF-899D-EB11D7C6772BQ35226150-160D9AF8-F51F-429C-B2F1-BAE6E6DE0DD8Q35590985-80042ADB-BF0A-49B4-89FF-030D176F855BQ36311022-1FB81BBD-8B2C-492A-AC99-07EF6B6A99EFQ36389654-77010174-FA56-4E8F-BE0A-6496AD7A2FF6Q36491834-37D6F06B-65D1-46C3-A27B-159F6F17D538Q36648476-EA6C33AF-4FAE-4783-8BE2-414A0220D779Q36746621-8347BDCE-31C9-40DB-A33F-E9C9EFC312C1Q36792147-E8E1DB43-CD2B-4EBD-ABD5-5F58394FCA80Q36799361-2A48FF97-A7E3-403A-80FB-A8C57907086FQ36836781-521E7B2F-DBE5-49B0-8090-7B667C144EC3Q36853970-6F351C44-0577-4811-9492-EEF383B888CBQ36914029-00A1BE6B-B786-45D3-B44C-9A57B6943F9AQ36944017-F2D15CFE-5376-40AA-BE07-EBF446153728Q36959712-3FBF49CE-0D3B-4D61-BABD-68A68C21CECCQ37038168-3D873289-0D9D-4257-97EA-DD0F4DD80D76Q37096227-D167CF93-9BCB-482A-B450-C9B8E55A0455Q37203807-22442731-19E9-4A9D-A731-EA96439B75D5Q37230351-DE42D4C5-B794-4AEA-AE6D-05D4F898693BQ37791316-5644A463-95A8-412E-BDC0-BA2339D865FEQ37983613-AEB99B0F-7F27-430F-90B1-8CED73FCAC2DQ38002290-06B2F234-A8F0-45E8-A9EA-EC5FB91758A7Q38154181-25CFAB78-FF91-4947-9D7B-5AC8D781043BQ38208293-A8A78F1F-7DDD-4075-ACDE-0960A4C8BBAC
P2860
Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Comparing guanfacine and dextr ...... eficit/hyperactivity disorder.
@en
Comparing guanfacine and dextr ...... eficit/hyperactivity disorder.
@nl
type
label
Comparing guanfacine and dextr ...... eficit/hyperactivity disorder.
@en
Comparing guanfacine and dextr ...... eficit/hyperactivity disorder.
@nl
prefLabel
Comparing guanfacine and dextr ...... eficit/hyperactivity disorder.
@en
Comparing guanfacine and dextr ...... eficit/hyperactivity disorder.
@nl
P1476
Comparing guanfacine and dextr ...... eficit/hyperactivity disorder.
@en
P2093
P304
P356
10.1097/00004714-200104000-00015
P407
P577
2001-04-01T00:00:00Z